Gasdermin (GSDM/Gsdm) family was originally identified as a candidate causative gene for a mouse skin mutation, recombination induced mutation 3 (Rim3). It has four human homologs, GSDMA, GSDMB, GSDMC, and GSDMD. All GSDM family members are located in amplicons, genomic regions often amplified during cancer development, and are considered to be involved in the regulation of epithelial apoptosis. GSDMA is mainly expressed in the upper gastrointestinal tract. In contract, GSDMD is expressed in the colorectal tract.

In this study, we researched those expressions in colorectal cancer and evaluated them for tumor marker, comparing between those expressions and clinical pathological status.

We immunohistologically analyzed both expressions of GSDMA and GSDMD, using thirty colorectal cancer cases which were surgically treated at our institution 2013-2014 (Stage1 10 cases, Stage2 10 cases, Stage3a 10cases). Thenretrospectively analyzed the connection, between GSDM expression and clinicopathological data.

GSDMA was no expressed in normal colorectal epithelium, but was overexpressed gradually rising in carcinoma.

However, GSDMD showed the opposite results compared with GSDMA.

The results of the expression analysis suggested that GSDMA and GSDMD act antagonictically with each other in the clinical stage of colorectal cancer.

Citation Format: Hajime Orita, Shigekazu Tanaka, Shunsuke Watanabe, Hirokazu Matsuzawa, Konomi Mizuguchi, Tomoaki Ito, Koji Senuma, Tomoyuki Kushida, Mutsumi Sakurada, Hiroshi Maekawa, Ryo Wada, Koichi Sato. The efficacy of Gasdermin gene family for tumor marker in colorectal cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3424. doi:10.1158/1538-7445.AM2015-3424